Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tìm kiếm cho các phương pháp điều trị kháng virus mới | 61 cổ phần 89%, 30% và 60% tương đồng với IFN alfa, IFN beta và IFN omega, tương ứng. CIFN phân tử liên kết với các thụ thể IFN-alfa với ái lực cao hơn so với tất cả các khác được biết đến IFN alfa phân tử (bao gồm cả các tuýp phụ tự nhiên, các biến thể hoặc recombinants). | Searching for new antiviral therapies 61 shares an 89 30 and 60 homology with IFN alfa IFN beta and IFN omega respectively. The CIFN molecule binds to the IFN-alfa receptor with higher affinity than all other known IFN alfa molecules including the natural subtypes the variants or recombinants . In vitro it appears to be approximately 5 to 20fold more active than PegIFN alfa-2a and alfa-2b Gonzalez 2009 . Data derived from clinical trials support the use of CIFN for treatment-naive patients particularly those with high VL or genotype 1 infection Sjogren 2005 as well as in the retreatment of relapsers and nonresponders Leevy 2008 . Clinical trials suggested a dose-dependent rate of viral clearance however the maximum tolerated dose of daily CIFN in difficult-to-treat patients is up to 15 pg day Bacon 2009 . Administration of an induction dose up to 18pg day or of a higher dose 24pg day did not translate to better rates of SVRs and was associated with more serious AEs and more discontinuations Meyer 2010 . CIFN is approved as monotherapy for CHC in adults with compensated liver disease and from 2010 for retreatment of CHC in combination with RBV being especially effective for interferon-sensitive patients with lower baseline fibrosis scores. IFN lambda IFN-Z is a type III interferon comprising of IL28A IL28B and IL29 which has previously demonstrated strong antiviral activity and good tolerability. IFN-Z mediates antiviral activity through a different signaling pathway than type I interferons such as IFN alfa having a complex binding mainly through the IL28 receptor which is present only on plasmacytoid dendritic cells peripheral B cell hepatocytes and epithelial cells. This restricted distribution compared to that of IFN-alfa receptor offers the potential for more targeted hepatic delivery as well as for a better tolerability and safety profile than the conventional interferons in terms of bone marrow suppression Sommereyns 2008 . IFN-Z can enhance the subsaturating
